Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Common Equity (2018 - 2025)

Historic Common Equity for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to -$6.1 million.

  • ImmunoTech's Common Equity fell 30868.82% to -$6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year decrease of 30868.82%. This contributed to the annual value of -$1.3 million for FY2024, which is 11291.77% down from last year.
  • ImmunoTech's Common Equity amounted to -$6.1 million in Q3 2025, which was down 30868.82% from -$6.5 million recorded in Q2 2025.
  • ImmunoTech's 5-year Common Equity high stood at $30.1 million for Q2 2023, and its period low was -$6.5 million during Q2 2025.
  • Moreover, its 3-year median value for Common Equity was $3.9 million (2024), whereas its average is $5.9 million.
  • In the last 5 years, ImmunoTech's Common Equity crashed by 7975.11% in 2024 and then tumbled by 30868.82% in 2025.
  • ImmunoTech's Common Equity (Quarter) stood at $10.2 million in 2023, then plummeted by 112.92% to -$1.3 million in 2024, then plummeted by 359.68% to -$6.1 million in 2025.
  • Its last three reported values are -$6.1 million in Q3 2025, -$6.5 million for Q2 2025, and -$3.9 million during Q1 2025.